Tag: MMAE
Clinical Phase I Data for ASG-15ME and Enfortumab Vedotin (ASG-22ME) Indicates...
Clinical data for ASG-15ME and Enfortumab vedotin, also known as ASG-22ME and ASG-22M6E, presented at the American Society of Clinical Oncology's (ASCO) 51st Annual Meeting held June...
Studies Show Glembatumumab Vedotin to be Effective in a Wide Range...
During the annual meeting of the American Association for Cancer Research (AACR) being held April 16 - 20, 2016 in New Orleans, LA, Celldex...
Glembatumumab Vedotin in Patients with Metastatic gpNMB-overexpressing Triple-negative Breast Cancer
Researchers have, in the last decades, made major advances in the development of therapies for breast cancer by identifying key markers known to drive...
Improving Hodgkin Lymphoma Treatment: Brentuximab Vedotin Data Supports Foundation of...
Final pivotal trial results in relapsed/refractory Hodgkin lymphoma (HL) demonstrate durable remissions lasting more than five years after brentuximab vedotin (Adcetris®; Seattle Genetics) monotherapy. Oral...
First of Two Planned Trials Combining Brentuximab Vedotin and Nivolumab Start...
Seattle Genetics, a biotechnology company focused on the development and commercialization of innovative antibody-based therapies for the treatment of cancer, has initiated a phase 1/2...
Analysis of Phase III AETHERA Data Demonstrates Brentuximab Vedotin Consolidation Therapy...
Several new analysis of Phase III data from the AETHERA trial (NCT01100502) demonstrate that brentuximab vedotin (Adcetris®; Seattle Genetics) consolidation therapy significantly extends progression-free...
Brentuximab Vedotin Data from the AETHERA Post-Transplant Consolidation Setting Presented at...
Data from brentuximab vedotin (Adcetris®; Seattle Genetics) in the AETHERA post-transplant consolidation setting for Hodgkin lymphoma (HL) and in frontline diffuse large B-cell lymphoma...
Phase I Trial of SGN-LIV1A Initiated in LIV-1-Positive Metastatic Breast Cancer
A new phase I clinical trial was initiated late October 2013 to evaluate SGN-LIV1A in patients with LIV-1-positive metastatic breast cancer. SGN-LIV1A is based...
Harnessing the Power of Three: Advancing Antibody-Drug Conjugates from Laboratory to...
Antibody-drug conjugates or ADCs are creating much excitement among life science professionals, medical/clinical research scientists and pharmaceutical specialists. At the same time, oncologists and hematologists are eager to welcome new treatment options in the ongoing war against cancer. This article reviews some of the advances made in the development of ADCs.
Anti-CD22 Monomethyl Auristatin Antibody-drug Conjugate Offers Potential Treatment for Non-Hodgkins Lymphoma
Antibody-drug conjugates (ADCs) are target-specific anticancer agents consisting of cytotoxic drugs covalently linked to a monoclonal antibody. They allow specific targeting of drugs to neoplastic...
